Sponsor: Daiichi Sankyo (industry)
Phase: 3
Start date: March 27, 2025
Planned enrollment: 510
Ifinatamab deruxtecan (I-DXd; DS-7300; MK-2400) is an investigational B7-H3–directed antibody–drug conjugate (ADC) from Daiichi Sankyo and Merck. It has shown antitumor activity across several solid tumors, with the most mature results in previously treated extensive-stage small cell lung cancer (ES‑SCLC). I-DXd received U.S. FDA Breakthrough Therapy Designation on August 18, 2025 for ES‑SCLC after platinum-based chemotherapy, supported by the phase 2 IDeate‑Lung01 trial. Phase 3 trials are ongoing in relapsed SCLC (IDeate‑Lung02) and in metastatic castration‑resistant prostate cancer (IDeate‑Prostate01). Press release (FDA BTD); WCLC 2025 IASLC news; JCO phase 3 SCLC trial-in-progress abstract; Phase 3 prostate cancer study initiation. (daiichisankyo.us)
Small cell lung cancer (SCLC)
Other tumors (phase 1/2, multi‑cohort; updated ESMO 2023 abstract 690P)
Ongoing confirmatory development
Notes - Reported results are from conference presentations and company/medical‑society communications through September 2025; peer‑reviewed, full‑text clinical publications for the phase 2 SCLC dataset were not identified at the time of this summary. (iaslc.org)
Last updated: Oct 2025
Goal: Evaluate whether ifinatamab deruxtecan (I-DXd), a B7-H3–targeted antibody-drug conjugate, improves overall survival versus investigator’s choice chemotherapy in previously treated unresectable or metastatic esophageal squamous cell carcinoma, with key secondary assessments of PFS and ORR.
Patients: Adults (≥18 years) with histologically/cytologically confirmed unresectable locally advanced or metastatic ESCC per AJCC 8th edition, after progression on exactly one prior line containing both platinum-based chemotherapy and an immune checkpoint inhibitor. Required: measurable disease by RECIST v1.1, ECOG 0–1, and adequate baseline tumor tissue. Key exclusions include prior B7-H3–directed therapy or topoisomerase I inhibitors, adenosquamous histology, lack of eligibility for all comparator chemotherapies, high-risk local invasion (e.g., aorta or airway), active/untreated symptomatic CNS metastases, recent arterial thromboembolic events or PE, significant corneal disease, history or current ILD/pneumonitis, severe pulmonary compromise, and chronic systemic steroids ≥10 mg prednisone equivalent daily.
Design: International, multicenter, randomized, open-label, phase 3 study. Participants are randomized to I-DXd versus investigator’s choice chemotherapy. Efficacy is assessed by blinded independent central review for imaging endpoints. Planned enrollment is 510.
Treatments: I-DXd: Ifinatamab deruxtecan 12 mg/kg IV every 3 weeks. I-DXd is an antibody-drug conjugate targeting B7-H3 (CD276), a transmembrane protein broadly expressed in solid tumors with limited normal tissue expression. The humanized anti–B7-H3 IgG1 is conjugated via cleavable linkers to a topoisomerase I inhibitor payload (DXd), delivering cytotoxic therapy selectively to B7-H3–expressing tumor cells. In pretreated extensive-stage small cell lung cancer, I-DXd has demonstrated objective response rates around 50% at 12 mg/kg with median PFS approximately 5–6 months and OS around 10–12 months; key toxicities include gastrointestinal and hematologic events and a risk of ILD/pneumonitis observed in roughly 9–12% of patients in those studies. Investigator’s choice chemotherapy: single-agent docetaxel, paclitaxel, or irinotecan, standard regimens for post–platinum/ICI ESCC.
Outcomes: Primary: Overall survival. Key secondary: PFS by BICR per RECIST v1.1 and ORR by BICR. Additional secondary endpoints include duration of response, disease control rate, patient-reported outcomes via EORTC QLQ-C30 and OES18, safety (TEAEs, serious TEAEs, AESIs including ILD/pneumonitis) per CTCAE v5.0, immunogenicity (anti-drug antibodies), and pharmacokinetics of I-DXd, total anti–B7-H3 antibody, and released payload (MAAA-1181a).
Burden on patient: Moderate. Treatment involves IV infusions every 3 weeks in both arms. The I-DXd arm includes intensive early pharmacokinetic sampling in cycle 1 (multiple draws up to 21 days postdose) with additional PK at cycles 2–5 and then every two cycles, adding visit time and venipunctures beyond standard care. Baseline tumor tissue submission is required, which may necessitate a new biopsy if archival tissue is inadequate. Imaging for RECIST assessments will follow typical phase 3 schedules and central review without additional procedures for patients. Safety monitoring is standard but will include vigilance for ILD/pneumonitis, potentially prompting additional pulmonary evaluations if symptoms arise. Travel burden aligns with q3-week infusions and scheduled assessments typical of second-line ESCC trials.
Last updated: Oct 2025
Inclusion Criteria:
Participants must meet all of the following criteria to be eligible for randomization into the study:
1. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old).
2. Has histologically or cytologically documented unresectable locally advanced or metastatic ESCC according to American Joint Committee on Cancer 8th edition staging system on ESCC.
3. Has disease progression post a platinum-based chemotherapy and an ICI treatment per global or local guidelines, with a maximum of 1 prior line of systemic therapy for unresectable advanced or metastatic ESCC.
4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content as defined in the Laboratory Manual.
5. Has at least 1 measurable lesion on computed tomography (CT)/magnetic resonance imaging (MRI) according to RECIST v1.1 as assessed by the investigator. Measurable lesions should not be from a previously irradiated site. If the lesion at a previously irradiated site is the only selectable target lesion, a radiological assessment showing significant progression of the irradiated lesion should be provided by the investigator.
6. Has an ECOG PS of 0 or 1 within 7 days prior to Cycle 1 Day 1.
Exclusion Criteria:
Participants who meet any of the following criteria will be disqualified from entering the study:
1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
2. Has received any topoisomerase inhibitor.
3. Has histologically or cytologically confirmed adenosquamous carcinoma subtype.
4. Is ineligible to all the chemotherapies in the comparator arm due to prior progression or intolerance.
5. Has tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of bleeding or fistula as assessed by the investigator.
6. Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive or treated brain metastases who are asymptomatic (ie, without neurologic signs or symptoms and not requiring treatment with corticosteroids or anticonvulsants) may be included in the study. Subjects must have a stable neurologic status and discontinue corticosteroid usage for at least 2 weeks prior to Screening.
7. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, other arterial thromboembolic event, or pulmonary embolism.
8. Has a clinically significant corneal disease.
9. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study randomization, severe asthma, chronic obstructive pulmonary disease \[COPD\], restrictive lung disease, pleural effusion, etc), and potential pulmonary involvement caused by any autoimmune, connective tissue, or inflammatory disorders (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), prior pneumonectomy, or requirement for supplemental oxygen.
11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/COPD), topical steroids (for mild skin conditions), or intra-articular steroid injections.
Jinan, 250117, China
No email / No phone
Status: Recruiting
Chengdu, 610041, China
No email / No phone
Status: Recruiting
Weihui, 453100, China
No email / No phone
Status: Recruiting
Tianjin, 453000, China
No email / No phone
Status: Recruiting
Wuhan, 430022, China
No email / No phone
Status: Recruiting
Xiamen, 361004, China
No email / No phone
Status: Recruiting
Brest, 29609, France
No email / No phone
Status: Recruiting
Milan, 20133, Italy
No email / No phone
Status: Recruiting
Nagoya, 464-8681, Japan
No email / No phone
Status: Recruiting
Kōtoku, 135-8550, Japan
No email / No phone
Status: Recruiting
Hiroshima, 734-8551, Japan
No email / No phone
Status: Recruiting
Sapporo, 060-8648, Japan
No email / No phone
Status: Recruiting
Kita-gun, 761-0793, Japan
No email / No phone
Status: Recruiting
Yokohama, 241-8515, Japan
No email / No phone
Status: Recruiting
Shinjuku-ku, 160-8582, Japan
No email / No phone
Status: Recruiting
Ōsaka-sayama, 589-8511, Japan
No email / No phone
Status: Recruiting
Kobe, 650-0047, Japan
No email / No phone
Status: Recruiting
Chūōku, 104-0045, Japan
No email / No phone
Status: Recruiting
Kashiwa, 277-8577, Japan
No email / No phone
Status: Recruiting
Osaka, 541-8567, Japan
No email / No phone
Status: Recruiting
Saitama, 362-0806, Japan
No email / No phone
Status: Recruiting
Matsuyama, 791-0280, Japan
No email / No phone
Status: Recruiting
Sunto-gun, 411-8777, Japan
No email / No phone
Status: Recruiting
Suita-shi, 565-0871, Japan
No email / No phone
Status: Recruiting
Craiova, 200542, Romania
No email / No phone
Status: Recruiting
Bucharest, 13823, Romania
No email / No phone
Status: Recruiting
Comuna Floresti, 407280, Romania
No email / No phone
Status: Recruiting
Suceava, 720284, Romania
No email / No phone
Status: Recruiting
Seoul, 5505, South Korea
No email / No phone
Status: Recruiting
Hwasun-gun, 58128, South Korea
No email / No phone
Status: Recruiting
Incheon, 21565, South Korea
No email / No phone
Status: Recruiting
Seoul, 8308, South Korea
No email / No phone
Status: Recruiting
Daegu, 700-721, South Korea
No email / No phone
Status: Recruiting
Goyang-sisouth, 10408, South Korea
No email / No phone
Status: Recruiting
Seoul, 6351, South Korea
No email / No phone
Status: Recruiting
Seongnam-si, 13620, South Korea
No email / No phone
Status: Recruiting
Seoul, 3722, South Korea
No email / No phone
Status: Recruiting
Seoul, 6591, South Korea
No email / No phone
Status: Recruiting
Kaohsiung City, 833, Taiwan
No email / No phone
Status: Recruiting
Tainan City, 70403, Taiwan
No email / No phone
Status: Recruiting
Taipei, 100225, Taiwan
No email / No phone
Status: Recruiting
Taipei, 11217, Taiwan
No email / No phone
Status: Recruiting
Detroit, Michigan, 48202, United States
No email / No phone
Status: Recruiting
Memphis, Tennessee, 38120, United States
No email / No phone
Status: Recruiting
Fort Worth, Texas, 76104, United States
No email / No phone
Status: Recruiting
Taichung, 40447, Taiwan
No email / No phone
Status: Not yet recruiting